Literature DB >> 32269211

ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer.

Dian Liu1, Ayse Ertay2, Charlotte Hill2, Yilu Zhou2,3, Juanjuan Li2, Yanmei Zou1, Hong Qiu1, Xianglin Yuan1, Rob M Ewing2,3, Xin Lu4, Hua Xiong5, Yihua Wang6,7,8,9.   

Abstract

The apoptosis-stimulating protein of p53 (ASPP) family of proteins can regulate apoptosis by interacting with the p53 family and have been identified to play an important role in cancer progression. Previously, we have demonstrated that ASPP2 downregulation can promote invasion and migration by controlling β-catenin-dependent regulation of ZEB1, however, the role of ASPP1 in colorectal cancer (CRC) remains unclear. We analyzed data from The Cancer Genome Atlas (TCGA) and coupled this to in vitro experiments in CRC cell lines as well as to experimental pulmonary metastasis in vivo. Tissue microarrays of CRC patients with information of clinical-pathological parameters were also used to investigate the expression and function of ASPP1 in CRC. Here, we report that loss of ASPP1 is capable of enhancing migration and invasion in CRC, both in vivo and in vitro. We demonstrate that depletion of ASPP1 could activate expression of Snail2 via the NF-κB pathway and in turn, induce EMT; and this process is further exacerbated in RAS-mutated CRC. ASPP1 could be a prognostic factor in CRC, and the use of NF-κB inhibitors may provide new strategies for therapy against metastasis in ASPP1-depleted CRC patients.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32269211      PMCID: PMC7142079          DOI: 10.1038/s41419-020-2415-2

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  54 in total

1.  ASPP proteins specifically stimulate the apoptotic function of p53.

Authors:  Y Samuels-Lev; D J O'Connor; D Bergamaschi; G Trigiante; J K Hsieh; S Zhong; I Campargue; L Naumovski; T Crook; X Lu
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

2.  Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.

Authors:  Ka-Kui Chan; Oscar Gee-Wan Wong; Esther Shuk-Ying Wong; Karen Kar-Loen Chan; Philip Pun-Ching Ip; Ka-Yu Tse; Annie Nga-Yin Cheung
Journal:  Int J Cancer       Date:  2018-05-02       Impact factor: 7.396

3.  Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome.

Authors:  Victor C Y Mak; Lee Lee; Michelle K Y Siu; Oscar G W Wong; Xin Lu; Hextan Y S Ngan; Esther S Y Wong; Annie N Y Cheung
Journal:  Mod Pathol       Date:  2010-11-19       Impact factor: 7.842

4.  SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence.

Authors:  X D Wang; E Lapi; A Sullivan; I Ratnayaka; R Goldin; R Hay; X Lu
Journal:  Cell Death Differ       Date:  2010-08-27       Impact factor: 15.828

5.  Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation.

Authors:  Victor C Y Mak; Lee Lee; Michelle K Y Siu; Oscar G W Wong; Xin Lu; Hextan Y S Ngan; Esther S Y Wong; Annie N Y Cheung
Journal:  Carcinogenesis       Date:  2013-05-13       Impact factor: 4.944

6.  ASPP1 and ASPP2: common activators of p53 family members.

Authors:  Daniele Bergamaschi; Yardena Samuels; Boquan Jin; Sai Duraisingham; Tim Crook; Xin Lu
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 7.  ASPP [corrected] and cancer.

Authors:  Giuseppe Trigiante; Xin Lu
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

8.  iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.

Authors:  Daniele Bergamaschi; Yardena Samuels; Nigel J O'Neil; Giuseppe Trigiante; Tim Crook; Jung-Kuang Hsieh; Daniel J O'Connor; Shan Zhong; Isabelle Campargue; Matthew L Tomlinson; Patricia E Kuwabara; Xin Lu
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

9.  Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation.

Authors:  Bin Song; Qi Bian; Yi-Jie Zhang; Cheng-Hao Shao; Gang Li; An-An Liu; Wei Jing; Rui Liu; Ying-Qi Zhou; Gang Jin; Xian-Gui Hu
Journal:  Mol Cancer       Date:  2015-10-05       Impact factor: 27.401

10.  Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma.

Authors:  Ka-Kui Chan; Esther Shuk-Ying Wong; Ivy Tsz-Lo Wong; Claire Ling-Yang Cheung; Oscar Gee-Wan Wong; Hextan Yuen-Sheung Ngan; Annie Nga-Yin Cheung
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

View more
  3 in total

Review 1.  Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.

Authors:  Sattar Khashkhashi Moghadam; Babak Bakhshinejad; Ali Khalafizadeh; Bashdar Mahmud Hussen; Sadegh Babashah
Journal:  J Cell Mol Med       Date:  2021-12-14       Impact factor: 5.310

2.  WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer.

Authors:  Ayse Ertay; Huiquan Liu; Dian Liu; Ping Peng; Charlotte Hill; Hua Xiong; David Hancock; Xianglin Yuan; Marcin R Przewloka; Mark Coldwell; Michael Howell; Paul Skipp; Rob M Ewing; Julian Downward; Yihua Wang
Journal:  Cell Death Dis       Date:  2020-11-21       Impact factor: 8.469

3.  CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.

Authors:  Minghui Zhang; Jianli Ma; Qiuyue Guo; Shuang Ding; Yan Wang; Haihong Pu
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.